Longer-lasting Botox competitor nabs FDA approval — can it compete with AbbVie's $2B...

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Sep 08, 2022 at 11:22: AM
via Revance Therapeutics announced Thursday that its first FDA approval has finally arrived for its Botox competitor, known as Daxxify, after initially submitting its original BLA way back in January 2020.

article source
 

<



Similar threads

cafead
Drug shortages are lasting longer, driven by economic pressures: US Pharmacopeia report
Replies
0
Views
52
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Vertex presents longer-term data that shows durability and consistency of Casgevy
Replies
0
Views
10
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
DCTs no longer? Decentralized solutions in post-pandemic clinical trials
Replies
0
Views
12
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Oncologists&#039; meetings with drug reps don&#039;t help cancer patients live longer
Replies
0
Views
51
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Luigi Naldini: Gene therapy no longer a ‘dream’ but big pharma must step up
Replies
0
Views
66
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote